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Abstract
A tremendous improvement in every aspect of breast cancer management has occurred in the last two decades.
Surgeons, once solely interested in the extipartion of the primary tumor, are now faced with the need to incorpo-
rate a great deal of information, and to manage increasingly complex tasks.
As a comprehensive assessment of all aspects of breast cancer care is beyond the scope of the present paper, the
current review will point out some of these innovations, evidence some controversies, and stress the need for the
surgeon to specialize in the various aspects of treatment and to be integrated into the multisciplinary breast unit
team.
Introduction
No other solid cancer has witnessed such a tremendous
change and improvement in terms of diagnosis and
management as breast cancer in the last 2 decades. This
remains the most common cancer among women
worldwide [1].
Breast cancer management has become increasingly
complex, and requires a comprehensive assessment of
multiple tasks in addition to the simple extirpation of
the primary tumor, including breast imaging, advanced
pathology, nuclear medicine and a variety of adjuvant
therapies, both local and systemic. This has shifted
breast cancer treatment into a multidisciplinary science.
Only a few decades ago, women with breast cancer
were uniformly treated with radical mastectomy and
total axillary dissection to achieve good loco-regional
control and the possibility of full recovery. Conservative
and selective surgical approaches to the breast and to
the axilla, once viewed with scepticism, have now
become standard of therapy for most patients [2,3].
Earlier detection and more effective treatments have
resulted both in an increasing percentage of small breast
cancers found at the initial diagnosis and in a small
decline in mortality [2].
Howewer, as the current goal for breast cancer
patients is “conservation” instead “the more radical exci-
sion the better”, the impact of local recurrence on
survival remains a relevant issue, and is presently a sub-
ject of research and debate.
The aims of this review are to analyze the most
important changes which have occurred in the last sev-
eral years in the surgical management of breast cancer
patients and to review some relevant issues such as sen-
tinel lymph node biopsy, the impact of local therapy on
survival, and the aesthetic results.
Non Palpable Lesions and Localization Techniques
Breast cancer screening has dramatically increased the
diagnosis of suspicious, non-palpable breast lesions, and
therefore also the need to localize them in order to plan
surgical treatment [4]. Furthermore, patients with a
breast cancer removed with clear margins at the first
excision seem to have a decreased risk of local recur-
rence compared with patients who need further re-exci-
sions to achieve negative margins [5].
This represents a “hot” topic in breast surgery, since
approximately 50% of breast cancers in modern surgical
practices are non palpable, and this incidence is cer-
tainly destined to increase [6].
Today, pre-operative confirmation of malignancy is
almost always achieved by fine-needle or core-biopsy,
and therefore, we need to localize these small cancers to
allow a one-step precise and directed excision.
Compared with their palpable counterpart, non-palp-
able lesions are associated with both a lower stage of
disease and a substantially decreased incidence of lymph
node involvement [7]. * Correspondence: lfortunato@hsangiovanni.roma.it
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used to identify small nodules, microcalcifications or
parenchymal distorsions. Howewer, it has some disad-
vantages such as pain and discomfort in some patients,
and occasionally carries risks of complications including
dislodgement of the wire, intraoperative wire transec-
tion, retention of wire fragments, thermal injury with
the use of cautery, hematoma and even syncope. WL is
performed in most institutions as an additional proce-
dure, outside the operating room, with further problems
related to organization and scheduling.
Successful localization with free margins of resection
is not always achieved with this technique and failures,
with consequent re-excisions, are reported in up to 33%
of cases [6-10].
A precise localization of a breast tumor with the wire
is not always possible, and the angle of access and tra-
jectory depends, in part, on the radiologist’sa b i l i t y .
Furthermore, the introduction of the wire directly above
the lesion may be technically problematic, especially
under stereotaxic guidance in locations such as the
inferior quadrants.
For this reasons several new techniques have been
introduced in order to achieve breast tumor localization.
Radioguided occult lesion localization (ROLL) is a use-
ful method to detect nonpalpable lesions through the
injection of a nuclear tracer (99 m TC-labelled colloidal
albumin) directly around the tumor under ultrasound or
stereotaxic guidance. Then, the excision of the primary
tumor is guided by a gamma probe, and a sentinel node
biopsy can be performed at the same time if needed
[11-13].
Unlike the WL, the procedure is generally more
straightforward and well tolerated, and the success rate
is reported to be very high [14-23] (Table 1).
Although ROLL has been shown to be comparable to
WL in at least 2 restrospective [24,25] and four prospec-
tive-randomized studies [19,20,22,26] with regards to the
ability to identify the lesion, four reports have demon-
strated a statistical difference in achieving tumor-free
margins in favor of the former technique [17,24,26,27].
Another technique for localization of non-palpable
breast tumors is represented by intraoperative ultra-
sound (IOUS).
It satisfies most requirements for an ideal technique to
localize non-palpable breast tumors which are well
visualized by ultrasound, while directing planes of sur-
gery during the excision. This in turn is helpful in guar-
anteeing both negative margins and an adequate
contour of resection in order to minimize the volume of
excision.
Identification rate of non-palpable lesions and free
margins of resection obtained through this procedure
are extremely high [28-34] (Table 2).
Furthermore, microcalcifications, usually visible only
by mammography, are sometimes associated with sono-
graphic alterations that can be detected, and removal of
such lesions under ultrasound guidance can sometimes
be performed [35].
Implications of Local Therapy
As conservative approaches have developed in the last
three decades and represent the standard of care for
breast cancer patients around the world, the incidence
of local recurrence (LR) has been widely studied. It
occurs in 5-10% of patients at 10 years, and it is more
pronounced in the first 3 or 4 years after primary sur-
gery [36,37].
Although several factors have been associated with the
risk of LR, at the multivariate analysis only age, status of
surgical margins and postoperative radiotherapy seem to
be independently correlated with it [38]. Patients with
multifocal tumors, once uniformely thought to be asso-
ciated with a higher risk of LR, and therefore treated
with mastectomy, are now often offered breast conserva-
tion, when technically feasible, as most studies seem to
indicate that the LR rate is not higher in these cases
than previous reports for unifocal cancers [39]. Simi-
larly, infiltrating lobular carcinoma is probably not asso-
ciated with a higher incidence of LR compared to the
ductal counterpart if resected with negative margins
[40].
Table 1 Complete excision rate of non palpable lesions
by ROLL
Author Year N Complete excision rate (%)
Gennari [14] 2000 647 99
Tanis [15] 2001 45 87
Ronka [16] 2004 215 93
Thind [17] 2005 68 84
Van Rijk [18] 2007 293 89
Moreno [19] 2008 61 93
Medina-Franco [20] 2008 50 89
Lavouè [21] 2008 72 85
Van Esser [22] 2008 40 78
Sarlos [23] 2009 100 98
Table 2 Identification rate of small lesions by US
Author Year N Identification (%) Free Margins (%)
Harlow [28] 1999 65 100 97
Smith [29] 2000 81 100 96
Kaufman [30] 2003 100 100 90
Bennett [31] 2005 103 100 93
Ngo [32] 2007 70 96 94
Haid [33] 2007 299 100 100
Fortunato [34] 2008 77 100 97
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many reports have shown that this is increased three-
fold for women less than 40 years of age [38,41-43].
Furthermore, younger patients show a statistically signif-
icant reduction of LR in several “boost trials”,a g a i n
demonstrating the importance of an appropriate local
therapy particularly in this age group [44].
It is interesting to note that despite the widespread
use of conservative approaches in breast cancer patients,
there is no general agreement even on the definition of
“negative” margins, and many describe such as the
absence of tumor at the microscopic or inked margin,
or with 1-3 mm clearance. It is clear that a high percen-
tage of patients whose tumors are 2-5 mm from the
radial margins have residual disease at re-excision [45].
For this reason, and despite best efforts, as many as 20-
25% of patients in many institutions around the world
return to the operating room after initial surgery for re-
excision [46]. While many reports fail to describe a sta-
tistically significant impact of margins on LR, most
would agree that one of the primary goals of conserva-
tive surgery is the removal of the primary tumor with a
portion of normal breast tissue, so as to maintain a
good breast shape [47-54].
Although the results of six prospective randomized
trials in patients with invasive breast cancer have
demonstrated that lumpectomy/quadrantectomy plus
RT and mastectomy have equivalent survival results
[55-60], it is worthwhile to remember that the first
conservation trial, the Guy’s wide excision study
initiated in the 60’s, has shown a decreased survival in
the group treated conservatively [61]. This suggests
that poor surgical removal of the primary tumor, pos-
sibly with dubious margins and without inking of the
specimen, together with employment of suboptimal
post-operative radiotherapy, may lead to a negative
impact not only on local control but also on survival
[57,61].
Although additional retrospective data has been accu-
mulated in the last few years suggesting that failure of
local control has an impact on survival [62], the most
striking evidence comes from the EBCTCG meta-analy-
sis [63].
This has shown that adjuvant RT after BCS not only
may improve local control, but it may also reduce 15-
year breast cancer mortality. The effect of radiation on
LC seems more pronounced in node positive patients,
while the effect on survival remains important both for
node-negative and node-positive patients [64,65].
This has lead many to suggest that for every four
women for whom local failure is prevented, one life
can be saved. As this disease is prevalent, and LR after
quadrantectomy and radiation is far from being an
exceptional event, this seems quite an important issue.
Minimalistic approaches are no longer viable for
women with breast cancer, and the aim of the contem-
porary surgeon is to team up with all available specia-
lists, and to coordinate efforts to reach the goal of local
control.
Skin Sparing Mastectomy
Although breast conservation surgery (BCS) has become
the gold standard for patients with early breast cancer,
mastectomy remains an option and it is necessary in at
least 20% of those women with multicentric tumors,
widespread DCIS, and large or recurrent tumors [66].
Sometimes the risk of an unpleasant cosmetic result
with conservative surgery to achieve tumor-free margins,
or personal desire to avoid radiation therapy plays a role
in the decision process.
New options are now available for these women and
they represent the forefront of the surgical therapy for
breast cancer patients.
Oncologic need to remove the skin envelope or the
nipple-areola complex has never been proved, and has
been lately challenged on solid evidence and back-
ground. Immediate breast reconstruction (IBR), a proce-
dure once discouraged for some years after primary
surgery because of fear of relapse, is now performed
routinely for an increasing number of patients. This has
a profoundly positive psychological effect, and allows for
a more solid recovery of these women so touched by
this disease [67].
Skin sparing mastectomy (SSM) has been increasingly
used in the last 15 years to improve cosmesis because
the skin envelope is preserved and the surgical access is
limited to a small elliptical incision around the areola
[68]. Our understanding that skin involvement is rare is
corroborated by pathologic studies, and when present, it
is usually over the primary tumor site, or is found in
cases with advanced disease, skin tethering, or lymphatic
emboli [69]. However, as maximal skin preservation is
desirable, special technical considerations are to be
addressed by the surgeon because the risk of leaving
some glandular tissue behind can be as high 10% if skin
flaps are more than 5 mm thick [70].
Clinical experience has confirmed so far that SSM has
very acceptable results in terms of local control even in
those studies with longer follow-up and is comparable
to modified radical mastectomy both in terms of local
control and survival [71-86] (Table 3).
Complications after SSM and immediate breast recon-
struction are reported in about 15% of cases, and
include flap necrosis and implant loss [87-89].
However, this risk must be weighed with the advan-
tage in cosmetic result and in patient satisfaction (as
defined by perception of body image, social activity and
sexual aspects), because these outcomes are better in
SSM with IBR compared with radical mastectomy [84].
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nely perform SSM to allow the plastic surgeon to inter-
vene more comfortably at the same time. Sometimes,
post-operative radiation therapy may be needed, and
although several studies and current clinical recommen-
dation report that the rate of complication is too high if
an implant is inserted in this setting [74,90-92], in
recent years a few studies have reassessed this issue
[93-96]. We believe that this is still an option in selected
cases, as it allows the patient to start more readily adju-
vant systemic therapies if needed, and when it fails, it
does not preclude or negatively influence possible auto-
logus conversion or final outcome.
Nipple-Sparing Mastectomy
“Nipple sparing mastectomy” (NSM) is the ultimate
challenge of this process which aims for an interaction
between conservative techniques and radical surgery. In
this procedure, the skin flap covering the breast gland
and the nipple-areola complex (NAC) are preserved. In
some cases the major ducts are removed.
In the past, the nipple has been routinely removed for
fear of occult tumor involvement, although this has
probably been overestimated. Many clinical studies have
shown that this involvement varies from 6 to 23%
depending on the size of the primary tumor, its location,
multicentricity, lymph node positivity and the presence
of extensive intraductal component [97-102] (Table 4).
We believe that this occurrence is rare in modern
clinical practice and although the risk is real, patients
can probably be safely selected for this approach.
Nevertheless, exact indications and contraindications
to this procedure are not well defined, and the incidence
of nipple involvement is reported to be as high as 50%
for tumors measuring more than 4 cm or located closer
than 2 cm from the nipple [103]. Therefore, the best
candidates for NSM are patients with no large tumor
(T1-T2), with lesions at least 1 cm from the areola or 2
cm from the nipple, or small multicentric carcinomas
[101].
Furthermore, nipple involvement is rare if the retroar-
eolar margin is free of disease [104].
A strategic issue is to avoid partial or total nipple or
areola necrosis because, although this can be easily trea-
ted postoperatively and under local anesthesia, it results
in psychological distress to the patient, and it must be
considered a failure of the procedure itself.
T h er a t eo fn i p p l en e c r o s i sv a r i e sf r o m0t o1 5 %
[101,105-110] (Table 5).
Surgical technique is extremely important. It is now
well understood that the use of periareolar incisions
should be abandoned, as it negatively affects the vascu-
lar supply of the nipple-areola complex, and that either
a radial or a lateral incision seem to be more effective in
this regard [109].
Although it is not clear how much tissue can or
should be left under the NAC, or if “nipple coring”
(removal of the terminal ducts from the inside of the
nipple papilla) should be performed (and how aggres-
sively), results of NSM can been examined in a few ret-
rospective studies published so far, and the local
recurrence rate is shown to be quite low in the majority
of them [103,106,107,110-115] (Table 6).
The role of post-operative radiotherapy following
NSM is unknown at the present, although a three-fold
decrease in the rate of locoregional failure has been
reported in one series [116]. However, in this retrospec-
tive study only large tumors (> 3 cm) were included,
and the site of failure is not clearly described.
Proponents at the European Institute of Oncology
have recently updated their experience reporting on
1,001 patients treated with a single intra-operative radio-
therapy treatment (21 Gy) with electrons (ELIOT) to the
NAC after NSM in the assumption that this single
radiation dose may sterilize occult cancer foci eventually
left in the glandular tissue behind the areola [115]. This
is the largest experience with NSM, to date, and the
incidence of local recurrence is reported at 1.4% with a
Table 3 Recurrence Rates after SSM
Author Year N LR (%) F/U (mo)
Slavin [71] 1998 51 2 45
Newman [72] 1998 372 6 25
Simmons [73] 1999 77 4 60
Kroll [74] 1999 114 7 72
Rivadeneira [75] 2000 71 6 49
Medina-Franco [76] 2002 176 4 73
Foster [77] 2002 67 4 49
Carlson [78] 2003 565 5 65
Greenway [79] 2005 225 2 49
Margulies [80] 2005 50 0 8
Yano [81] 2007 124 2 34
Patani [82] 2008 83 0 34
Scholz [83] 2008 72 0 42
Ueda [84] 2008 74 5 50
Garwood [85] 2009 64 1 13
Gerber [86] 2009 238 10 101
Table 4 Occult Histologic Nipple Involvement
AUTHOR YEAR PATIENTS (N) NIPPLE INVOLVEMENT (%)
Santini [97] 1989 1291 12
Laronga [98] 1999 286 6
Sikand [99] 2005 220 7
Vlajciz [100] 2005 108 23
Petit [101] 2006 106 10
KG [102] 2008 397 15
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cerns have been raised regarding the possible negative
effects (even long-term) on the vascularity of the NAC
after a single large dose of radiotherapy, the usefulness
of this approach is appealing but currently unproven. Of
interest, in a subgroup of patients, treated with ELIOT,
with very close tumor margins under the areola, no
local recurrence was observed.
Oncoplasty
Oncoplasty has been developed in the last 15 years as a
new surgical approach and incorporates a variety of
relatively simple, common plastic techniques. This has
generated much enthusiasm around the world, among
both by breast and plastic surgeons, and in the UK for-
mal oncoplasty training has been developed [117].
Indeed, oncoplastic surgery represents a step forward
in breast conservation, allowing us to treat tumors in
problematic locations (for example in the lower quad-
rants), to avoid poor cosmetic results, asymmetry or
unpleasant scarring in the upper quadrants, and to
obtain wider excisions and tumor free margins [118].
Oncoplasty is safe, as no statistical differences in
terms of local relapse and disease-free survival are evi-
denced when comparing classic quadrantectomies and
oncoplastic approaches [118-120]. It should be consid-
ered for those patients where adequate local excision
cannot be achieved without a significant risk of local
deformity, as it frequently occurs in resection of more
than 20% of breast volume, or for tumors located in the
central, medial or inferior quadrants. Other indications
include women considering a breast reduction in addi-
tion to excision.
Several volume displacement techniques can be
employed, including glandular remodelling, inferior or
superior pedicle flaps, round block excision, and the
Grisotti flaps. Their description is beyond the scope of
this review.
Centrally located tumors account for 5 to 20% of
breast cancer cases and have long been thought to be
associated with a higher incidence of multicentricity and
multifocality [121,122]. However, other more recent
reports have failed to substantiate a specific correlation
between location of the tumor and multicentricity
[123,124]. For this reason, they represent an important
challenge for breast surgeons, as they have been classi-
cally treated with a mastectomy, and until few years ago
only 7% of central breast cancers were treated with con-
servative surgery [119].
Several studies on the local recurrence rate after cen-
tral quadrantectomy, each with a small number of
patients, show very acceptable results even long-term
[125-132] (Table 7).
A direct comparison between central quadrantectomy
and mastectomy has seldom been studied, and no signif-
icant differences in terms of local failure and overall sur-
vival have been reported [119,127,133-135]. However,
these reports are limited by their retrospective nature
and may not be comparable because mastectomy was
Table 5 Nipple Necrosis after NSM
AUTHOR YEAR N PARTIAL NECROSIS % TOTAL NECROSIS %
Crowe [105] 2004 48 6 0
Caruso [106] 2006 50 2 0
Sacchini [107] 2006 192 7 4
Petit [101] 2006 106 10 5
Komorowski [108] 2006 38 5 8
Stolier [109] 2008 82 0 0
Voltura [110] 2008 51 6 0
Table 6 Nipple Sparing Mastectomy: Local Recurrence
AUTHOR YEAR N LOCAL RECURRENCE % FOLLOW-UP (months)
Simmons [111] 2004 17 0 24
Caruso [106] 2006 50 2 66
Sacchini [107] 2006 123 2 25
Denewer [112] 2007 41 0 8
Crowe [113] 2008 149 3 41
Voltura [110] 2008 51 6 18
Sookhan [103] 2008 18 0 11
Gerber [114] 2009 61 12 101
Petit [115] 2009 1001 1.4 20
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tive non-randomized study has been published so far,
and it has confirmed an equivalent outcome in terms of
local or systemic disease [132].
We believe that by adhering to the principles of
breast-conserving surgery, including complete resection
of the primary tumor with a negative margin, these cen-
trally located tumors can be treated adequately by nip-
ple-areolar resection. Adjuvant radiation therapy to the
remainder of the breast can treat subclinical microscopic
disease, if present, with accepTable local control and
adequate cosmesis.
Sentinel Lymph node Biopsy, and Management of Special
Circumstances
Lymph node involvement is the single most important
prognostic factor for survival in breast cancer patients,
and consequently information about it provide both sta-
ging information and guidance regarding treatment
options [136].
SLN biopsy is now considered an adequate axillary
staging procedure for patients who have breast cancer
because it is easy and reproducible if carried out by
experienced clinicians, and carries less morbidity com-
pared to axillary node dissection [137].
Many concerns were raised in the past because SLN
biopsy can result in some false-negative cases. A recent
meta-analysis of 69 trials found the rate of false nega-
tives to be about 7% of the node-positive patients [138].
Much of what is known today regarding SLN biopsy
in breast cancer does not result from randomized trials.
The procedure has been accepted quickly by most dedi-
cated surgeons around the world on the basis of a grow-
ing body of evidence that SLN is effective. Often, patient
demand has overcome the caution that surgeons usually
demonstrate before abandoning a well-tested procedure,
such as axillary node dissection. In some cases, rando-
mized trials have been prematurely closed because of
problems in accrual, either because randomization was
not acceptable to patients, or because surgeons, after
acquiring sufficient experience with SLN biopsy, were
unwilling to allow their patients to enter the trial.
Enhanced pathology of the SLN has generated much
confusion and even controversy, but it is a key point as
different results can be obtained by different groups
using different protocols. A survey of the European
Working Group for Breast Screening Pathology reported
that 240 pathologists replying to a questionnaire
described some 123 different pathology protocols [139].
The authors’ group recently has proposed a simple,
practical standardized protocol, with slicing at three
levels at 100-micron intervals and double staining with
both hematoxylin and eosin (H&E) and immunohisto-
chemistry (MNF116) (Figure 1) [140]. This protocol has
allowed our pathologists to increase the diagnosis of
additional nodal disease by nearly two-thirds compared
with standard, single-section analysis of the lymph
nodes stained with H&E, although the majority of this
gain is represented by minimal disease, micrometastases
or isolated tumor cells. (Figure 1)
Some important issues, such as the prognostic influ-
ence of SLN micrometastases, and the use of SLN
biopsy in special circumstances are still subject of open
debate among clinicians.
T h ep r o g n o s t i cs i g n i f i c a n c eo fm i c r o m e t a s t a s e si n
SLN is controversial. Its diagnosis is rapidly increasing
(17% per annum since 1997) as reported by a recent
analysis of the SEER database of 175,000 patients treated
between 1990 and 2002 [141]. This probably results
from a combination of factors, including the diagnosis
of smaller tumors by mammographic screening, and the
implementation of SLN biopsy with more frequent diag-
nosis of minimal node involvement by step sectioning.
In the most important retrospective study, conducted
by the International (Ludwig) Breast Cancer Study
Group, 9% of 921 patients who had negative axillary
lymph nodes on routine H&E single-section analysis
w e r ef o u n dt ob en o d ep o s i t i v eo ns e r i a ls e c t i o n i n g
[142]. In some, but not in all, groups these women had
a significantly poorer 5-year disease-free and overall sur-
vival rate. Recent data seem to confirm the hypothesis
that micrometastases are indeed a marker of poorer
prognosis.
In a review of the published literature in 1997, Dow-
latshahi [143] analyzed all large and long-term studies
and confirmed a statistically significant decrease in sur-
vival associated with the presence of axillary node
micrometastases. The group at Memorial Sloan Ketter-
ing Cancer Center has used serial sections and immuno-
histochemistry to re-evaluate all axillary lymph nodes
from 373 patients operated in the 1970s who were
deemed to be node negative by routine histopathology
[144]. The presence of any detectable micrometastatic
disease was associated with decreased disease-free and
overall survival rates.
Table 7 Local Recurrence after Central Quadrantectomy
AUTHOR YEAR N LR % FOLLOW-UP (Months)
Galimberti [125] 1993 37 0 32
Haffty[126] 1995 98 6 108
Simmons[127] 2001 32 6 60
Pezzi[128] 2004 15 6 32
Tausch [129] 2005 44 7 51
Naguib [130] 2006 23 9 13
Huemer[131] 2007 31 0 34
Wagner [132] 2007 31 0 42
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Page 6 of 17Figure 1 A simple and standardized protocol, with slicing at three levels at 100-micron intervals and double staining with both
hematoxylin-eosin and immunohistochemistry, that has allowed the pathologists in the authors’ group to diagnose additional nodal
disease with an increment of nearly two thirds compared with standard, single-section analysis of the lymph nodes stained with
hematoxylin-eosin. (Adapted from Fortunato L, Amini M, Costarelli L, et al. A standardized sentinel lymph node enhanced pathology protocol
(SEPP) in patients with breast cancer. J Surg Oncol 2007;96[6]:471; with permission.)
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Institute of Oncology from 1997 to 2000, Colleoni and
colleagues [145] have found that minimal involvement
(micrometastases or isolated tumor cells) of a single
lymph node correlated with decreased disease-free survi-
val and doubled the risk of distant metastases.
Recently, the presence of isolated tumor cells or
micrometastases in the SLN were found to be associated
with a reduced 5-year disease-free survival among 856
women in the Netherlands with favorable early-stage
breast cancer who did not receive adjuvant therapy. In
this study, an additional cohort of 995 patients who
received adjuvant therapy showed an improved disease-
free survival at a median follow-up of five years [146].
At the present time, surgical management and sys-
temic options in case of SLN micrometastases are con-
troversial. Most retrospective studies have reported a
substantial rate of additional lymph node metastases in
patients with SLN micrometastases, with a wide range
between reports, making one think that patient selection
is a key in determing the choice of candidates for com-
pletion lymph node dissection [147-154] (Table 8).
Ongoing or completed/closed randomized trials such
as the ACOSOG Z0010, the National Surgical Adjuvant
Breast and Bowel Project B32 and the International
Breast Cancer Study Group 23-01, will help to fully
understand whether further axillary treatment should be
mandatory when the SLN is positive [155-157].
There are still a few clinical settings in which SLN
biopsy generates controversy, and we would like to
review some of them:
Ductal Carcinoma In Situ (DCIS)
Management of DCIS is clinically relevant, because its
incidence is increasing and represents today approxi-
mately 20-25% of newly diagnosed cases of breast cancer
[158].
Traditionally, axillary node metastases were identified
by conventional histology in fewer than 2% of patients
whose surgical specimen was interpreted as containing
D C I So n l y ,p r o b a b l yb e c a u s et h ep r e s e n c eo fi n v a s i v e
cancer can be unrecognized [159].
Studies of patients with “pure” DCIS who have under-
gone SLN biopsy have confirmed an extremely low rate
of axillary node involvement [160,161]. Unfortunately,
the diagnosis of “pure” DCIS can be misleading because
microinvasion can be missed even with an extensive his-
tologic search and immunostaining, and because a preo-
perative diagnosis is not always feasible due to sampling
error after microbiopsy. A recent meta-analysis, includ-
ing 22 published reports, has estimated that the inci-
dence of SLN metastases in patients with a pre-
operative diagnosis of DCIS is 7.4%, compared with an
incidence of 3.7% for patiens with a definitive (post-
operative) diagnosis of DCIS [162].
In DCIS with diagnosed microinvasion the incidence
of axillary metastases has been reported to range from
3% to 10% in small series [163-173] (Table 9).
In case of SLN involvement after diagnosis of DCIS, it
is not clear whether a complete axillary node dissection
should be performed, or additional systemic therapy be
considered. A review of 21 series collected only 29 such
patients undergoing axillary lymphadenectomy after a
positive SLN finding, and no additional metastases were
found after completion of lymphadenectomy [174].
Recurrent Breast Cancer
Approximately 10% of breast cancer patients are
expected to experience an ipsilateral recurrence 10 to 15
years after their initial treatment.
Although patients who have an ipsilateral recurrence
of breast cancer are at increased risk of systemic relapse,
their prognosis is not uniformly bad, and approximately
two thirds of patients are alive at 5 years [175]. Until
recently, axillary re-evaluation was not indicated in
these cases.
Recent studies, however, have suggested that a repeat
SLN can be performed after a previous SLN biopsy, and
sometimes after an axillary node dissection. This has the
potential to alter clinical management, as it may help to
stratify the risk of systemic disease, and to consider the
need of additional systemic therapies.
For a recurrent breast cancer, a repeat SLN biopsy
seems more successful after a previous SLN biopsy than
Table 8 Additional Positive Non Sentinel Metastases for Micrometastatic SLN
AUTHOR YEAR SLN (N) MICROMETASTASES (%) POSITIVE NON-SLN (%)
Reynolds [148] 1999 220 27 22
Turner [149] 2000 514 42 22
Nos [150] 2003 800 33 7
Hwang [151] 2003 627 21 57
Fan [152] 2005 390 29 17
Rutledge [153] 2005 358 25 3
Schrenk [154] 2005 966 39 18
Van Rijk[155] 2006 2150 30 19
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Page 8 of 17after an axillary node dissection, and in this setting SLN
positivity is not uncommon [176-185] (Table 10).
The risk of an extra-axillary localization (parasternal,
interpectoral, or supraclavicular region or to the contral-
ateral axilla) is reported in approximately one-third of
cases, particularly after a previous AND.
Neoadjuvant Chemotherapy
An area of particular interest is the use of SLN biopsy in
patients undergoing neoadjuvant chemotherapy, because
the number of patients choosing this option is
increasing.
Until recently, feasibility and accuracy of SLN biopsy
in these patients were considered limited due to the
possible alteration of lymphatic patterns after che-
motherapy, but several studies have reached different
conclusions.
Data reported in the literature show an identification
rate from 71 to 100% and a false-negative rate less than
13% [186-205] (Table 11).
Our group, however, favors SLN biopsy before begin-
ning of neoadjuvant therapy, as pathologic stage, along
with complete response, are still the most important
prognostic factors for these patients who so frequently
belong to a young age group. Securing stage allows a
more precise knowledge of the risk for the single
patient; it allows meaningful comparison between differ-
ent neoadjuvant protocols; and in case of negativity, it
allows a simple tumorectomy after therapy for those
patients with good responses.
Multicentric Breast Cancers
Multicentric breast cancer may occur in up to 10% of
cases. SLN biopsy is also accurate in these patients,
because SLN drains the whole breast, regardless of
tumor localization, as reported by many studies
[206-216] (Table 12).
In the largest report to date, a study from the Austrian
Sentinel Node Study Group, a retrospective comparison
between 142 patients with multicentric and 3,216
patients with unicentric cancers, showed no difference
in detection of the SLN, or false-negative rates [211].
Therefore, we believe that SLN should be considered
standard of care for these tumors.
Although either multiple Tc-99 injections or a single
intradermal injection over the largest-size lesion has
been described, a single periareolar injection of the tra-
cer has been proposed as a mean to simplify this techni-
cal aspect, and there evidence that this leads to the
identification of a single, representative SLN [212].
Internal Mammary Sln Biopsy
Although prospective randomized trials have not
demonstrated a therapeutic benefit of removal of inter-
nal mammary lymph nodes (IMN) in patients with
breast cancer [217], it is well known that involvement of
Table 9 SLN Biopsy in DCIS with Microinvasion
AUTHOR YEAR N SLN POSITIVITY (%)
Zavatosky [164] 1999 14 4
Klauber-De More [165] 2000 31 3
Wassergerg [166] 2002 57 3
Intra [167] 2003 41 10
Le Bouedec [168] 2005 107 7
Sakr [169] 2006 128 7
Zavagno [170] 2007 43 9
Fortunato [171] 2007 77 8
Doyle [172] 2009 145 5
Rubio [173] 2009 47 4
Polom [174] 2009 183 5
Table 10 SLN in Recurrent Breast Cancer
Author Year N Success after previous SLND
(%)
Success after previous ALND
(%)
Extra-axillary localization of SLN
(%)
Positive SLN
(%)
Sood [177] 2004 4 - 4/4 2/4 0/4
Agarwa l
[178]
2005 2 - 2/2 2/2 1/2
Roumen
[179]
2006 12 2/2 8/10 7/12 4/10
Newman
[180]
2006 8 1/8 7/7 10/10 0/7
Taback [181] 2006 15 5/6 6/9 8/15 3/11
Intra [182] 2007 65 65/65 - 5/63 7/63
Port [183] 2007 46 - 22/46 13/46 10/64
Barone [184] 2007 19 6/7 0/12 16/19 2/16
Axelsson
[185]
2007 46 - 22/46 13/46 7/22
Koizumi [186] 2008 31 3/31 16/31 14/23 4/28
TOTAL 248 82/119 (69) 87/167 (52) 90/240 (37) 38/227 (17)
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more, medial and inferior tumors have been reported to
drain more commonly to IMN [218], although this has
not been routinely taken in consideration in the last
decades. Indeed, the IMN represents an important path-
way, draining lymphatics from the deep breast lobules
along the pectoral fascia and intercostals muscles [219].
Several studied have shown that SLN biopsy of the
IMN is feasible, although it requires mapping through a
deep intraparenchimal or peritumoral injection, as IMN
identification is almost impossible after an intradermal
injection [220,221]. The procedure involves more com-
monly a direct exposure of the second or third intercos-
tal space, division of the intercostal muscle fibers, and is
associated with the rare possibility of breach of the
pleural cavity [222]. This has raised concerns regarding
the acceptability of this procedure if there is no defini-
tive demonstration of a survival benefit.
Studies have evidenced that SLN of IMN can be iden-
tified in 8-34% of breast cancer patients, and it can
potentially benefit 7-15% of such patients because of a
positive histologic finding [220,222-226]. Therefore, a
Table 11 Sentinel Lymph node biopsy after neoadjuvant chemotherapy
Author Year N Identification rate (%) False-negative rate (%)
Breslin [187] 2000 51 84 13
Tafra [188] 2001 29 93 0
Fernandez [189] 2001 40 85 22
Julian [190] 2002 34 91 0
Stearns [191] 2002 34 85 23
Brady [192] 2002 14 93 0
Schwartz [193] 2003 21 100 9
Piato [194] 2003 42 98 12
Reitsamer [195] 2003 30 87 7
Kang [196] 2004 54 72 11
Lang [197] 2004 53 94 4
Shimazu [198] 2004 47 94 12
Balch [199] 2004 32 97 5
Mamounas [200] 2005 428 85 12
Tausch [201] 2006 167 85 8
Newman [202] 2007 54 98 8
Shen [203] 2007 69 93 25
Kinoshita [204] 2007 104 93 10
Hino [205] 2008 55 71 0
Classe [206] 2009 195 90 11
TOTAL 1553 1345/1553 (87%) 68/538 (13%)
Table 12 SLN biopsy in multicentric breast cancers
Author Year N Identification rate (%) False negative rate (%)
Schrenk [207] 2001 19 100 0
Fernandez [208] 2002 53 98 0
Kumar [209] 2003 59 93 0
Tousimis [210] 2003 70 96 8
Goyal [211] 2004 75 95 9
Knauer [212] 2006 150 91 4
Ferrari [213] 2006 31 100 8
Gentilini [214] 2006 42 100 NR
D’Eredita [215] 2007 30 100 6
Cipolla [216] 2008 34 100 0
Lo Yf [217] 2009 135 100 0
TOTAL 698 666/698 (95%) 11/190 (6%)
Mascaro et al. World Journal of Surgical Oncology 2010, 8:5
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Page 10 of 17potential change in management in the whole group is
uncommon.
In case of IMN positivity adjuvant radiotherapy or sys-
temic therapy may be offered, and clinical trials would
be needed to determine whether it improves survival.
Breast Units: A Challenge For The Clinician
I nt h ep a s t ,af e ws t u d i e s[ 2 2 7 - 2 3 4 ]h a v ea n a l y z e dv a r -
ious high-risk surgical procedures (such as pancreatic or
hepatic surgery) and correlated post-operative outcomes
to hospital or surgeon procedure volume. The results of
these studies have strongly suggested that complex visc-
eral resections ought to be regionalized and concen-
trated in high volume hospitals.
Surprisingly, this rule may also apply to breast cancer
care, because even if the surgical skills required in most
cases are not usually complex, the need for a compre-
hensive, multidisciplinary management does seem to
play a difference. This has prompted a debate regarding
how to guarantee women with the best care possible
through a preferential access to specialized breast cancer
centers.
An analysis of some 233,000 operated breast cancer
patients extracted from a nationwide US database and
operated over a 13-year period has shown that the risk
of death was three times higher for patients treated at
low-volume hospitals, and that they were less likely to
receive breast conservation. Furthermore, the risk of
post-operative complications was higher and length of
stay was longer in this group [235].
A review of 24,834 patients from the Florida Cancer
Data System reported higher survival rates for patients
treated at teaching hospitals compared with community
or low-volume hospitals [235,236]. It was concluded
that much of these differences were due to the
decreased use of proven adjuvant therapies, again under-
lining the need for an integrated treatment for this
disease.
Not only hospital volume and type, but also surgeons’
experience, do make a difference. In a report of almost
30,000 patients operated in the Los Angeles County,
treatment by a surgical oncologist (a “specialist”)
resulted in a 33% reduction in the risk of death at 5
years at the multivariate analysis [237].
In the US this information has resulted in a rapid
increment of Breast Fellowship, recognizing that appro-
priate training is one of the key factors in improving
quality of care. Currently, the number of such subspe-
cialties almost equals that for surgical oncology. Never-
theless, until few years ago 25% of surgeons in the US
performed almost 90% of the surgery for breast cancer,
and probably this occurs even more frequently around
the world [238].
In Europe, the Florence and Hamburg [239,240] state-
ments have anticipated these findings as early as 1988,
and, through a joint effort of EORTC, the European
Society of Mastology (EUSOMA) and Europa Donna,
the innovative concept for standard guidelines of Breast
Units has been proposed to assure the best quality of
care to women with breast cancer.
The EUSOMA “Requirements of a Specialist Breast
Unit” was first published in 2000 and sets mandatory
criteria for accreditation. This revolutionary concept is
based on a process of voluntary accreditation; it was
established because hospitals will likely be eager to
claim that they have specialized breast units, and specia-
lists will wish to show that they work in recognized
units.
Requirements for accreditation indicate the need of
one Breast Unit every 250,000 total population, and
include at least 150 new cases of breast cases diagnosed
each year, a core team in which each member must
have special training in breast cancer (surgeon, radiolo-
gist, oncologist, pathologist, patient support staff, data
managers, psychologist, genetist), regular multidisciplin-
ary case management meetings, and adequate treatment
facilities for patients.
W en o wk n o wt h a tas e r v i c ep r o v i d e db yat r a i n e d
specialist is more efficient and more cost effective; diag-
nostic decisions are made earlier and unnecessary inves-
tigations avoided; operations conducted by specialists
produce better results for technical reasons; the inter-
pretation of imaging techniques and the reading of his-
tology is much more likely to produce definitive
opinions if carried out by experts.
All this is leading towards a radically different type of
organization for the treatment of breast cancer. This
change will be driven not much from “mandatory”
requirements, but by the willingness of more sophisti-
cated breast cancer patients to search for the most
appropriate treatment and the best possible results.
Conclusions
The “new era” of breast cancer treatment began more
three decades ago with the revolutionary concept of
breast conservation, and has not yet finished.
Clinical research, multidisciplinary approaches, and
sophisticated therapies are being sought by every
women newly diagnosed with breast cancer and hope-
f u l l yw i l lb em o r ea c c e s s i b l es ow ec a ni m p r o v et h e
overall quality of care for breast cancer treatment.
Surgeons must keep up with this process, and lead
future changes to reach the goal of complete recovery
for every patient.
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